|
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa Clinical research trials and Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa. Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa clinical trial. Subjects frequently get the best healthcare possible for their Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa  Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
For Condition: HIV Infections,HIV Seronegativity
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection. The study involves Southern African populations. The HIV-1 virus changes rapidly and many different subtypes have been found. In South Africa, limited data have suggested Subtype C HIV-1 is the most common. This study strives to verify the most common subtype and also look at genetic differences and immune responses among newly infected individuals. Results will aid in the development of vaccines specific for certain geographical areas.
Details: HIV-1 evolves rapidly and multiple genetic subtypes have been isolated from a number of geographic locations. There are limited data on the distribution of subtypes in the Southern African HIVNET sites. Data suggest subtype C HIV-1 predominates and this study is designed to substantiate and extend these observations to understand the biological relationship between HIV-1 subtypes, genetic variability, and immune responses. Earlier studies were conducted using individuals who had been seropositive for 3 to 9 years with advanced disease status; this study will test reactivity during the early stage of infection. This will assist in the rational selection of prototypic isolates for inclusion in either a single universal vaccine or vaccines tailored for specific subtypes/geographical regions. Volunteers are recruited from Malawi, South Africa, Zambia, and Zimbabwe. The earliest possible cases of seroconversion are included. At enrollment, participants are counseled appropriately for their HIV status and demographic information is obtained. Participants are followed quarterly up to 12 months. Epidemiological, clinical, and laboratory data are collected during physical exams and blood draws at each visit. Blood samples are used to assess CD4 counts, plasma viral load, genetic parameters, and individual immune responses. Participants who are seronegative or whose status is unknown are tested for HIV at each visit, with post-test counseling when participants return to the clinic for test results. In addition to enrolling the HIV-infected and uninfected volunteers, each site contributes a 5-ml blood sample from 50 seronegative individuals for DNA extraction and HLA genotyping.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: 18 Years/45 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Participants may be eligible for this study if they: - Are first HIV-negative and later test HIV-positive; or are HIV-positive and have evidence of being HIV-negative within the 8 months prior to first testing HIV-positive; or are HIV-positive with one test and HIV-negative with another test. Exclusion Criteria Participants will not be eligible for this study if they: - Have a mental disorder that interferes with agreeing to do the study or with participating in the study. - Are receiving anti-HIV treatment for more than 4 weeks. - Have tuberculosis.
Total Enrollment: 125
Location and Contact Information:
Overall Study Official:
HaynesSheppard, Study Chair,
Missie Allen
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: HIVNET 028;
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006298
Other Hiv Seronegativity Studies:
1. 4-Day-A-Week Treatment Plan for HIV Infected Adolescents
2. Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
3. A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia in AIDS
4. Effects of Immunization with HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
5. A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women
Related Studies:
Other HIV Seronegativity Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
|
|
|
|
|
|
|
|
